Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat - Gilead Sciences/Japan Tobacco

Drug Profile

Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat - Gilead Sciences/Japan Tobacco

Alternative Names: Elvitegravir/Truvada/GS 9350; EVG/COBI/FTC/TDF; EVG/FTC/TDF/cobicistat FDC Quad tablet; Quad; Stribild

Latest Information Update: 03 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences; Japan Tobacco
  • Class Antiretrovirals; Deoxyribonucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 27 Aug 2018 Japan Tobacco and Gilead sign a letter of intent to initiate discussion to terminate license agreement for elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat drug in Japan
  • 24 Jun 2018 Biomarkers information updated
  • 29 Jan 2018 Gilead Sciences completes a phase II/III trial in HIV-1 infections (In children, In adolescents, Treatment-naive) in USA, Thailand, South Africa (PO) (NCT01721109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top